How hypocretin agonists may improve the quality of wake in narcolepsy

Jessica L. Justinussen; Christine Egebjerg; Birgitte R. Kornum

doi:10.1016/j.molmed.2022.10.008

How hypocretin agonists may improve the quality of wake in narcolepsy

Jessica L. Justinussen, Christine Egebjerg, Birgitte R. Kornum^*

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

6 Citationer (Scopus)

Abstract

Excessive daytime sleepiness (EDS) is a complex symptom characterized by a strong urge to sleep during daytime accompanied by problems such as attention deficits, anxiety, and lower cognitive performance. The efficacy of treatments for EDS is determined by their ability to decrease sleepiness, and less attention has been given to the effects these compounds have on the quality of the wake itself. Hypocretin (HCRT; orexin) signalling is implicated in narcolepsy, and hypocretin receptor 2 (HCRTR2) agonists are in clinical trials for treating EDS in narcolepsy. Here, we review preclinical research to determine how HCRTR2 agonists may affect attention and anxiety compared with other EDS treatment strategies. We conclude that such compounds may improve not only the quantity but also the quality of wake, and we hope that they will create opportunities for more nuanced treatment strategies in narcolepsy

Originalsprog	Engelsk
Tidsskrift	Trends in Molecular Medicine
Vol/bind	29
Udgave nummer	1
Sider (fra-til)	61-69
Antal sider	9
ISSN	1471-4914
DOI	https://doi.org/10.1016/j.molmed.2022.10.008
Status	Udgivet - 2023

Bibliografisk note

Funding Information:
The work was supported by the Lundbeck Foundation (R344-2020-749 to C.E. B.R.K.) and a Carlsberg Foundation Young Researcher Fellowship (J.L.J. B.R.K.). B.R.K. has consulted for UCB Pharma, Lundbeck, Takeda, and Orexia Therapeutics. B.R.K. is a founder of the spin-out company Ceremedy ApS. All other authors declare that they have no competing interests.

Funding Information:
The work was supported by the Lundbeck Foundation ( R344-2020-749 to C.E., B.R.K.) and a Carlsberg Foundation Young Researcher Fellowship (J.L.J., B.R.K.).

Publisher Copyright:
© 2022 Elsevier Ltd

Adgang til dokumentet

10.1016/j.molmed.2022.10.008

Citationsformater

@article{74968c75a757417792e30bf429720424,

title = "How hypocretin agonists may improve the quality of wake in narcolepsy",

abstract = "Excessive daytime sleepiness (EDS) is a complex symptom characterized by a strong urge to sleep during daytime accompanied by problems such as attention deficits, anxiety, and lower cognitive performance. The efficacy of treatments for EDS is determined by their ability to decrease sleepiness, and less attention has been given to the effects these compounds have on the quality of the wake itself. Hypocretin (HCRT; orexin) signalling is implicated in narcolepsy, and hypocretin receptor 2 (HCRTR2) agonists are in clinical trials for treating EDS in narcolepsy. Here, we review preclinical research to determine how HCRTR2 agonists may affect attention and anxiety compared with other EDS treatment strategies. We conclude that such compounds may improve not only the quantity but also the quality of wake, and we hope that they will create opportunities for more nuanced treatment strategies in narcolepsy.",

keywords = "anxiety, attention, excessive daytime sleepiness treatment, hypocretin, narcolepsy, wake",

author = "Justinussen, {Jessica L.} and Christine Egebjerg and Kornum, {Birgitte R.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2023",

doi = "10.1016/j.molmed.2022.10.008",

language = "English",

volume = "29",

pages = "61--69",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd. * Trends Journals",

number = "1",

}

TY - JOUR

T1 - How hypocretin agonists may improve the quality of wake in narcolepsy

AU - Justinussen, Jessica L.

AU - Egebjerg, Christine

AU - Kornum, Birgitte R.

PY - 2023

Y1 - 2023

N2 - Excessive daytime sleepiness (EDS) is a complex symptom characterized by a strong urge to sleep during daytime accompanied by problems such as attention deficits, anxiety, and lower cognitive performance. The efficacy of treatments for EDS is determined by their ability to decrease sleepiness, and less attention has been given to the effects these compounds have on the quality of the wake itself. Hypocretin (HCRT; orexin) signalling is implicated in narcolepsy, and hypocretin receptor 2 (HCRTR2) agonists are in clinical trials for treating EDS in narcolepsy. Here, we review preclinical research to determine how HCRTR2 agonists may affect attention and anxiety compared with other EDS treatment strategies. We conclude that such compounds may improve not only the quantity but also the quality of wake, and we hope that they will create opportunities for more nuanced treatment strategies in narcolepsy.

AB - Excessive daytime sleepiness (EDS) is a complex symptom characterized by a strong urge to sleep during daytime accompanied by problems such as attention deficits, anxiety, and lower cognitive performance. The efficacy of treatments for EDS is determined by their ability to decrease sleepiness, and less attention has been given to the effects these compounds have on the quality of the wake itself. Hypocretin (HCRT; orexin) signalling is implicated in narcolepsy, and hypocretin receptor 2 (HCRTR2) agonists are in clinical trials for treating EDS in narcolepsy. Here, we review preclinical research to determine how HCRTR2 agonists may affect attention and anxiety compared with other EDS treatment strategies. We conclude that such compounds may improve not only the quantity but also the quality of wake, and we hope that they will create opportunities for more nuanced treatment strategies in narcolepsy.

KW - anxiety

KW - attention

KW - excessive daytime sleepiness treatment

KW - hypocretin

KW - narcolepsy

KW - wake

U2 - 10.1016/j.molmed.2022.10.008

DO - 10.1016/j.molmed.2022.10.008

M3 - Review

C2 - 36400667

AN - SCOPUS:85141961866

VL - 29

SP - 61

EP - 69

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 1

ER -